AJANTPHARM vs AMRUTANJAN: Stock Comparison
AJANTA PHARMA is the larger company by market capitalisation. AJANTA PHARMA shows a higher ROE, a higher dividend yield and faster revenue growth, while AMRUTAJAN HEALTH shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AJANTPHARM leads 8; AMRUTANJAN leads 2 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AJANTPHARM | AMRUTANJAN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AJANTPHARM | AMRUTANJAN |
|---|---|---|
| Live Price | ₹3,283.9 | ₹487.65 |
| Day Change | 0.41% | -1.88% |
| Volume | 1.55 L | 35,012 |
| 52-Week High | ₹3,796 | ₹760.15 |
| 52-Week Low | ₹2,382 | ₹476.5 |
| Distance from 52W High | -13.49% | -35.85% |
Valuation
| Metric | AJANTPHARM | AMRUTANJAN |
|---|---|---|
| Market Cap | ₹41,236 Cr | ₹1,408 Cr |
| P/E Ratio | 36.11x | 26.57x |
| P/B Ratio | 9.05x | 3.87x |
| EPS | ₹90.79 | ₹18.67 |
| Book Value | ₹362.35 | ₹128.04 |
| Dividend Yield | 1.96% | 1.51% |
Growth
| Metric | AJANTPHARM | AMRUTANJAN |
|---|---|---|
| Revenue Growth (TTM YoY) | 21.5% | 10.5% |
| EPS Growth (TTM YoY) | 18.6% | 6.7% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | AJANTPHARM | AMRUTANJAN |
|---|---|---|
| ROE | 22.42% | 15.64% |
| ROCE | 22.95% | 16.18% |
| Net Margin | 19.38% | 11.52% |
| Operating Margin | 25.46% | 15.54% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | AJANTPHARM | AMRUTANJAN |
|---|---|---|
| Promoter Holding | 63.47%▼ 0.01 pp | 46.52% |
| FII Holding | 7.63%▼ 0.05 pp | 3.47%▲ 1.03 pp |
| DII Holding | 21.94%▲ 0.14 pp | 6.9%▼ 5.38 pp |
| Public Holding | 6.96%▼ 0.07 pp | 43.08%▲ 4.36 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AJANTA PHARMA and AMRUTAJAN HEALTH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.